Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2SARS-CoV-2의 스파이크 단백질을 표적으로 하는 치료 항체 및 융합 억제제Editorial Published on 2021-06-012022-09-11 Journal: Expert opinion on therapeutic targets [Category] MERS, SARS, 진단, 치료제, [키워드] Abstract inhibitor N-terminal N-terminal domain Receptor-binding domain S2 subunit SARS-CoV-2 Spike protein the spike protein Therapeutic antibody therapeutic targets [DOI] 10.1080/14728222.2020.1820482 PMC 바로가기 [Article Type] Editorial
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteinsArticle Published on 2021-05-182022-10-04 Journal: Scientific Reports [Category] SARS, 임상, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibodies antibody applied binding Biotechnology cause clinical investigation clinical trial Coronavirus-2 COVID-19 disease domain Drug discovery ENhance etesevimab immunology Implementing IMPROVE Interaction limit magnitude methodological Molecular medicine neutralization p53 Protein pseudovirus infection SARS-CoV-2 SARS-CoV-2 antibody Spike protein Spike proteins the SARS-CoV-2 Therapeutic antibody variant variants of concern viral infection viral spike protein virus wildtype [DOI] 10.1038/s41598-021-89887-w PMC 바로가기 [Article Type] Article
Development and application of therapeutic antibodies against COVID-19COVID-19에 대한 치료 항체의 개발 및 적용Review Published on 2021-04-102022-09-12 Journal: International Journal of Biological Sciences [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome antibodies antibody antibody cocktail bamlanivimab caused Clinical stage clinical trial cocktail convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 antibody COVID-19 treatment development drug Emergency use etesevimab FDA food format Genome Health Health crisis Host monoclonal antibodies monoclonal antibody pandemic polyclonal antibodies problem proteome REGN-CoV2 SARS-CoV-2 Severe acute respiratory syndrome target targets therapeutic Therapeutic antibody therapeutic interventions therapy Transcriptome treating COVID-19 Treatment U.S. Food and Drug Administration [DOI] 10.7150/ijbs.59149 PMC 바로가기 [Article Type] Review
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016Report Published on 2021-04-052022-10-31 Journal: Cell Reports Medicine [Category] COVID-19, [키워드] Abstract addition Affect amino acid change antibody Antibody binding antibody cocktail antibody escape antigenic evolution B.1.351 B.1.429 bamlanivimab binding circulating Combination Complete coronavirus disease COVID-19 deep mutational scanning E484K Effect Efficacy effort epitope Evolution highlight identify individual Interpretation L452R Lineage LY-CoV555 Map monoclonal antibody Mutation P.1 Prophylaxis RBD SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 mutation SARS-CoV-2 RBD spike receptor-binding domain the SARS-CoV-2 therapeutic Therapeutic antibody variants of concern Variation [DOI] 10.1016/j.xcrm.2021.100255 PMC 바로가기 [Article Type] Report
Fully Human Antibodies for Malignant Pleural Mesothelioma TargetingReview Published on 2020-04-082023-08-30 Journal: Cancers [Category] E형 간염, [키워드] BCR repertoire fully human antibody Immunotherapy malignant pleural mesothelioma (MPM) mesothelioma MPM management phage display solid tumors targeting tertiary lymphoid structure (TLS) Therapeutic antibody [DOI] 10.3390/cancers12040915 PMC 바로가기 [Article Type] Review
Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding DomainArticle Published on 2019-02-192022-10-28 Journal: Viruses [Category] Coronavirus, [키워드] Ability antibody Antibody fragments approved binding conditions coronavirus country cross-neutralization cross-neutralizing dimeric domain effective elevated enhanced extreme greater high temperature MERS MERS-CoV MERS-CoV infection MERS-CoV RBD Middle East monomeric mortality rate Mutation nanobodies Neutralizing Neutralizing activity protease Protein RBD Receptor binding Receptor-binding domain relative reported significantly stability strain syndrome targeting the RBD therapeutic agent therapeutic antibodies Therapeutic antibody Treatment trimeric urea virus [DOI] 10.3390/v11020166 PMC 바로가기 [Article Type] Article